Memorial Sloan Kettering Cancer Center Psychopharmacology in Cancer Care 2023
Format: 10 videos + 17 pdfs, size: 6.19 GB
Course Audience: Psychiatrists, Psycho-oncologists, Oncologists, Palliative Care Physicians
Overview:
Date & LocationSaturday, April 22, 2023, 8:15 AM – 4:35 PM, Online, New York, NY
SpecialtiesSpecialties – Behavioral Care, Critical Care, General and Family Practice, Geriatric Medicine, Hematology, Integrative Medicine, Internal Medicine, Medical Oncology, Neurology, Nurse Anesthetist, Nurse Practitioner, Nursing, Pain Medicine, Psychiatry, Psychology, Social WorkOverviewClinicians have numerous tools at their disposal to help adult cancer patients dealing with symptoms of depression, anxiety, and other cancer sequelae. Psychiatric medications are most frequently prescribed to cancer patients by oncologists and general practitioners, however, psychiatric syndromes are often underdiagnosed and undertreated. Few oncology practices have dedicated psychiatric consultants familiar with the nuances of Psycho-Oncology. Even when patients receive psychotropic medications appropriately, they may have problems that arise before their next oncology visit or before they see the person who prescribed their psychiatric medications. Psychologists, nurses, and social workers play an essential role in identifying psychological and physical symptoms as well as both beneficial and problematic medication effects as they provide frontline psychosocial interventions and support for cancer patients.
This course is designed for the non-prescribing psycho-oncology clinician as well as the psychiatrist who is new to the world of Psycho-pharmaco-oncology. Oncologists, palliative care clinicians, advanced practice nurses, and oncology nurses will find this course useful as well. The course will focus on key target disorders and symptoms amenable to psychopharmacological intervention, including anxiety, depression, delirium, sleep disturbance, pain, fatigue, and weight and appetite loss. The course will also include updates on COVID-19-related delirium and the use of novel interventions including ketamine, medical marijuana, and psilocybin for depression, anxiety, and pain. Participants will learn to identify psychological reactions to medical conditions or treatments; psychiatric presentations of medical conditions or treatments; medical presentations of psychiatric conditions and common medical complications of psychiatric conditions or treatments.
Basic information will be presented about medications used to alleviate Quality of Life symptoms that arise in cancer setting from diagnosis to survivorship or end-of-life care, and the interface of psychotherapy and medication management. We will review why certain medications are used and why some are avoided, looking at potential benefits, unwanted side effects, and drug-drug interactions, since you may be the first person to identify a serious adverse event. The course will also enhance your ability to provide psychoeducation to patients regarding psychiatric medications.
This course is co-sponsored by the MSK Psycho-Oncology Education and Training Institute (POETI).
Who Should Attend
This course is intended for Psychiatrists, Psycho-oncologists, Oncologists, Palliative Care Physicians, Physician Assistants, Nurse Practitioners, Nurses, Psychologists, Social Workers and Counselors.
2023 Program Highlights
This year’s program includes topics on:
- Depressive Disorders (Andrew Roth, MD)
- Delirium (William Breitbart, MD)
- Anxiety Disorders (Andrew Roth, MD)
- Sleep Disorders (Yesne Alici, MD)
- Cancer-Related Fatigue (William Breitbart, MD)
- Pain (Natalie Moryl, MD)
- Weight and Appetite Loss (Yesne Alici, MD)
- Cancer and Cancer-Treatment Related Cognitive Changes (Yesne Alici, MD)
- Novel Psychopharmacologic Interventions in Oncology (Christian Bjerre Real, MD, MMCI, FAPA)
Additionally, there will be ample time during program breaks to meet the faculty and ask questions.
Objectives- Describe basic psycho-pharmaco-oncology principles for understanding and treating anxiety, depression and delirium in people with cancer.
- Discuss basic psycho-pharmaco-oncology principles for understanding and improving quality of life and psychiatric palliative care in people with cancer, including managing cognitive changes, insomnia, fatigue, poor appetite and weight loss, and pain.
- Identify the nuances of psycho-pharmaco-oncology related to COVID-19 related delirium and the use of novel interventions including ketamine, medical marijuana, and psilocybin for depression, anxiety, and pain in people with cancer.
Anxiety Disorders (Video MP4 Format)
Anxiety Disorders (PDF Format)Cancer and Cancer-Treatment Related Cognitive Changes (Video MP4 Format)Cancer and Cancer-Treatment Related Cognitive Changes (PDF Format)Cancer-Related Fatigue (Video MP4 Format)Cancer-Related Fatigue (PDF Format)Cannabis_Ketamine_MDMA_ Psilocybin Reference list (PDF Format)Delirium Handouts (PDF Format)Delirium (Video MP4 Format)Delirium (PDF Format)Depression Handouts (PDF Format)Depressive Disorders (Video MP4 Format)Depressive Disorders (PDF Format)Fatigue Handouts (PDF Format)Novel Psychopharmacologic Interventions in Oncology (Psilocybin, Ketamine, & Medical Marijuana) (Video MP4 Format)Novel Psychopharmacologic Interventions in Oncology (Psilocybin, Ketamine, & Medical Marijuana) (PDF Format)Overview and Introduction (Video MP4 Format)Overview and Introduction (PDF Format)Pain Handouts (PDF Format)Pain (Video MP4 Format)Pain (PDF Format)Psychopharm_2023_Brochure (PDF Format)Sleep Disorders (Video MP4 Format)Sleep Disorders (PDF Format)Weight and Appetite Loss Handouts (PDF Format)Weight and Appetite Loss (Video MP4 Format)Weight and Appetite Loss (PDF Format)